The Lin Law Firm Investigates Potential Breaches Of Fiduciary Duties In Connection With Proposed Acquisition Of Par Pharmaceutical Companies Inc.
LOS ANGELES, July 17, 2012 /PRNewswire/ -- The Lin Law Firm, A Professional Law Corporation, is investigating potential breach of fiduciary duty claims against the Board of Directors of Par Pharmaceutical Companies Inc. ("Par Pharmaceutical" or the "Company") (NYSE: PRX) related to the proposed acquisition of the Company by TPG Capital for $50 per share.
This investigation concerns whether the Board of Directors of Par Pharmaceutical breached its fiduciary duties to shareholders by failing to adequately shop the Company and to obtain the highest price for its shareholders, and whether all material information to shareholders has been disclosed. The Company has exceeded earnings expectations in three of the last four quarters, and its stock price reached as high as $42.58 on May 2, 2012. In addition, the price being offered for Par Pharmaceutical shares in the proposed acquisition is low compared to recent deals for generic drug makers.
If you currently own shares of Par Pharmaceutical and would like to learn more about these claims, or if you wish to discuss these matters and have any questions concerning this announcement or your rights, please contact Elizabeth Lin, Esq., The Lin Law Firm, APLC, by telephone at (866) 864-3898 or by email to elizabethL@thelinlawfirm.com.
The Lin Law Firm, A Professional Law Corporation, is a litigation law firm committed to representing investors nationwide in securities matters and protecting investors against corporate wrongdoing. For additional information, please visit www.thelinlawfirm.com.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact: Elizabeth Lin, Esq.The Lin Law Firm, A Professional Law Corporation2705 S. Diamond Bar Blvd., Suite 398 Diamond Bar, CA 91765Tel: (909) 595-5522 / Toll Free: (866) 864-3898Fax: (909) 595-5519 www.thelinlawfirm.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts